Gastrointestinal cancer is one of the highly prevalent malignant diseases worldwide which is a major cause of morbidity and mortality. Gastric cancer is the second leading cause of cancer mortality in the world and it...Gastrointestinal cancer is one of the highly prevalent malignant diseases worldwide which is a major cause of morbidity and mortality. Gastric cancer is the second leading cause of cancer mortality in the world and its management, especially in advanced stages, has evolved relatively little [1]. Colorectal cancer (CRC) remains the third most common ma-lignancy and the third leading cause of cancer death worldwide [2]. The surgical treatment is still the most effective therapy for the gastrointestinal cancer. However, the majority of the patients had lost the opporunity of surgical therapy when it was detected at advanced stage, so to seek means other than surgical treatment of gastrointestinal cancer metastasis and recur-rence also has an important significance. With the deeping research of the molecular biology, molecular targeted therapy has become the hotspot and focus of comprehensive treatment of gastrointestinal cancer which is proposed against the molecular biological targets such as tumor cell growth, apoptosis, cell cycle, invasion and angiogenesis. Molecular targeted therapy can be grouped into six main areas: the epidermal growth factor receptor (EGFR) inhibitors, anti-angiogenic factors, cell cycle inhibitors, apoptosis promoters and matrix metalloproteinase inhibitors, cyclooxygenase inhibitors. The review of the progress are as follows.展开更多
文摘目的:探讨在肿瘤细胞生物治疗单个核细胞采集中,影响终产品单个核细胞计数(mononuclear cell,MNC)和采集效率(collection efficiency,CE)的因素。方法:对共计142例肿瘤患者和健康供者的采集数据进行分析,包括年龄、性别、身高、体重、身体质量指数(body mass index,BMI)、全身血容量、诊断类别、血管通路、操作者、终产品量、ACD抗凝剂用量、流速、循环次数、采前血红蛋白(Hb)、红细胞计数(RBC)、血小板计数(Plt)、白细胞计数(WBC)、淋巴细胞计数、单核细胞计数、中性粒细胞计数、去掉抗凝剂的循环血量、终产品单个核细胞计数和单个核细胞的采集效率。其中单个核细胞CE(%)=终产品MNC×100/(采前MNC×去掉抗凝剂的循环血量)。采用T检验和多元线性回归分析研究影响终产品MNC和CE的因素。结果:肿瘤患者的CE高于健康供者(24.41±1.91,20.01±0.99,P=0.043),不同操作者之间CE不同(P=0.01,H=18.59)。终产品MNC与终产品容量、ACD抗凝剂用量、采前淋巴细胞计数呈正相关(P=0.00,P=0.01,P=0.00,r=0.811);MNC的CE与流速、采前RBC计数呈负相关,与操作者工作年限、ACD抗凝剂用量呈正相关(P=0.01,P=0.04,P=0.03,P=0.00,r=0.495)。结论:采前淋巴细胞计数越高、ACD抗凝剂用量和终产品容量越多,终产品MNC越多;ACD抗凝剂用量越多,操作者资历越高单个核细胞CE越高;采前RBC越高、采集流速越快,单个核细胞CE越低。
文摘Gastrointestinal cancer is one of the highly prevalent malignant diseases worldwide which is a major cause of morbidity and mortality. Gastric cancer is the second leading cause of cancer mortality in the world and its management, especially in advanced stages, has evolved relatively little [1]. Colorectal cancer (CRC) remains the third most common ma-lignancy and the third leading cause of cancer death worldwide [2]. The surgical treatment is still the most effective therapy for the gastrointestinal cancer. However, the majority of the patients had lost the opporunity of surgical therapy when it was detected at advanced stage, so to seek means other than surgical treatment of gastrointestinal cancer metastasis and recur-rence also has an important significance. With the deeping research of the molecular biology, molecular targeted therapy has become the hotspot and focus of comprehensive treatment of gastrointestinal cancer which is proposed against the molecular biological targets such as tumor cell growth, apoptosis, cell cycle, invasion and angiogenesis. Molecular targeted therapy can be grouped into six main areas: the epidermal growth factor receptor (EGFR) inhibitors, anti-angiogenic factors, cell cycle inhibitors, apoptosis promoters and matrix metalloproteinase inhibitors, cyclooxygenase inhibitors. The review of the progress are as follows.
